dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-27T11:28:55Z
dc.date.available2014-05-27T11:28:55Z
dc.date.created2014-05-27T11:28:55Z
dc.date.issued2013-04-12
dc.identifierCurrent Nanoscience, v. 9, n. 1, p. 159-167, 2013.
dc.identifier1573-4137
dc.identifier1875-6786
dc.identifierhttp://hdl.handle.net/11449/75108
dc.identifier10.2174/157341313805117857
dc.identifierWOS:000317836000026
dc.identifier2-s2.0-84875934477
dc.description.abstractThe chronic hyperproliferative diseases (CHD) include cancer, precancerous lesions and diseases of unknown etiology such as psoriasis. Various drugs have been used in the treatment of CHD, such as antiproliferative and corticosteroids in general. However, some drugs have properties that limit their effectiveness, such as low solubility in water and low penetration of the skin. Thus, the control of drug release in the skin may improve efficacy and reduce side effects of many drugs used in hyperproliferative diseases. The purpose of this study was to make a systematic review of nanotechnology-based drug delivery systems used against hyperproliferative skin diseases. © 2013 Bentham Science Publishers.
dc.languageeng
dc.relationCurrent Nanoscience
dc.relation1.306
dc.relation0,292
dc.rightsAcesso restrito
dc.sourceScopus
dc.subjectChronic hyperoproliferative diseases
dc.subjectDrug delivery systems
dc.subjectNanotechnology
dc.subjectPsoriasis
dc.subjectSkin cancer
dc.subjectSkin diseases
dc.subjectSkin treatment
dc.subjectAnti-proliferative
dc.subjectDrug delivery system
dc.subjectDrug release
dc.subjectSkin cancers
dc.subjectSkin disease
dc.subjectSolubility in waters
dc.subjectSystematic Review
dc.subjectDermatology
dc.subjectDisease control
dc.subjectDrug delivery
dc.subjectDrug interactions
dc.subjectDrug products
dc.subjectDiseases
dc.subjectaminolevulinic acid
dc.subjectbenzopsoralen 3 ethoxy carbonyl 2h benzofuro[3,2 e] 1 benzopiran 2 one
dc.subjectchitosan derivative
dc.subjectclobetasol propionate
dc.subjectcorticosteroid
dc.subjectetretin
dc.subjectfluorouracil
dc.subjectglycerol behenate
dc.subjectketoprofen
dc.subjectmethotrexate
dc.subjectmethoxsalen
dc.subjectn sulfonate n,o carboxymethylchitosan
dc.subjectnanocapsule
dc.subjectnanocoating
dc.subjectpaclitaxel
dc.subjectphosphatidylcholine
dc.subjectpodophyllotoxin
dc.subjectpoloxamer
dc.subjectpolymer
dc.subjectpolymeric nanoparticle
dc.subjectpolymethacrylic acid
dc.subjectpsoralen derivative
dc.subjectretinoic acid
dc.subjectsolid lipid nanoparticle
dc.subjectspantide
dc.subjecttacrolimus
dc.subjecttemoporfin
dc.subjecttriamcinolone acetonide
dc.subjectunclassified drug
dc.subjectbiodegradability
dc.subjectburning sensation
dc.subjectcell differentiation
dc.subjectcell viability
dc.subjectchronic hyperproliferative disease
dc.subjectcontact dermatitis
dc.subjectcream
dc.subjectdermatitis
dc.subjectdrug absorption
dc.subjectdrug cytotoxicity
dc.subjectdrug delivery system
dc.subjectdrug efficacy
dc.subjectdrug penetration
dc.subjectdrug release
dc.subjectdrug retention
dc.subjectdrug safety
dc.subjectdrug solubility
dc.subjectencapsulation
dc.subjecterythema
dc.subjecthuman
dc.subjectinjection site pruritus
dc.subjectiontophoresis
dc.subjectkeratinocyte
dc.subjectliquid crystal
dc.subjectmicroemulsion
dc.subjectnanomedicine
dc.subjectnanotechnology
dc.subjectphotochemotherapy
dc.subjectphotodynamic therapy
dc.subjectphotosensitivity
dc.subjectprecancer
dc.subjectpriority journal
dc.subjectpsoriasis
dc.subjectPUVA
dc.subjectskin allergy
dc.subjectskin cancer
dc.subjectskin disease
dc.subjectskin infection
dc.subjectskin penetration
dc.subjectskin tumor
dc.subjectstratum corneum
dc.subjectsystematic review
dc.subjectT lymphocyte
dc.subjecttopical treatment
dc.subjectultraviolet A radiation
dc.subjectultraviolet B radiation
dc.titleNanotechnology-based drug delivery systems for treatment of hyperproliferative skin diseases - a review
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución